AbbVie Lowers Full-Year 2025 EPS Guidance Due to $1.3 Billion Q4 IPR&D Expense
ABBV sits 40% above its 52-week low of $164.39 on elevated volume (1.8× avg).
Summary
AbbVie revised its full-year 2025 adjusted diluted EPS guidance to $9.90-$9.94, down from $10.61-$10.65, primarily due to a $1.3 billion acquired IPR&D and milestones expense incurred in the fourth quarter of 2025.
Key Events · Earnings and Guidance · ABBV
-
Revised Full-Year 2025 EPS Guidance
AbbVie's full-year 2025 adjusted diluted EPS guidance is now $9.90 - $9.94, a reduction from the previously announced range of $10.61 - $10.65.
-
Q4 2025 IPR&D Expense Impact
The company expects to include $1.3 billion in acquired IPR&D and milestones expense on a pre-tax basis for the fourth quarter of 2025, resulting in an unfavorable impact of $0.71 per share on both GAAP and adjusted non-GAAP diluted EPS.
-
Updated Q4 2025 EPS Guidance
The adjusted diluted EPS guidance for Q4 2025, including the IPR&D expense, is now projected to be $2.61 - $2.65.
Analysis · ABBV · Life Sciences
AbbVie's updated guidance reflects a significant, albeit non-recurring, expense related to acquired in-process research and development (IPR&D) and milestones. While the $1.3 billion pre-tax charge for Q4 2025 is substantial and reduces the full-year EPS outlook, the company notes that such expenses are not typically forecasted due to their uncertain nature and timing. Investors will need to consider whether this IPR&D investment is strategically beneficial for future growth, despite the immediate negative impact on reported earnings.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.5% of the 1882 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.18%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABBV was trading at $229.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $412.5B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.